NASDAQ: ADPT

Adaptive Biotechnologies Corp Stock Forecast, Predictions & Price Target

The consensus among 2 Wall Street analysts covering (NASDAQ: ADPT) stock is to Buy ADPT stock.

Out of 2 analysts, 1 (50%) are recommending ADPT as a Strong Buy, 0 (0%) are recommending ADPT as a Buy, 1 (50%) are recommending ADPT as a Hold, 0 (0%) are recommending ADPT as a Sell, and 0 (0%) are recommending ADPT as a Strong Sell.

If you're new to stock investing, here's how to buy Adaptive Biotechnologies stock.

(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual revenue growth rate of 14.1% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 63.47%, and while it is forecast to beat the US market's average forecast revenue growth rate of 6.63%.

Adaptive Biotechnologies's revenue in 2023 is $179,690,000.On average, 5 Wall Street analysts forecast ADPT's revenue for 2023 to be $25,525,462,820, with the lowest ADPT revenue forecast at $24,640,322,220, and the highest ADPT revenue forecast at $26,855,345,311. On average, 5 Wall Street analysts forecast ADPT's revenue for 2024 to be $33,358,682,058, with the lowest ADPT revenue forecast at $29,678,413,955, and the highest ADPT revenue forecast at $36,813,973,306.

In 2025, ADPT is forecast to generate $42,897,469,076 in revenue, with the lowest revenue forecast at $41,014,120,358 and the highest revenue forecast at $46,233,033,259.

According to 2 Wall Street analysts that have issued a 1 year ADPT price target, the average ADPT price target is $8.00, with the highest ADPT stock price forecast at $10.00 and the lowest ADPT stock price forecast at $6.00.

On average, Wall Street analysts predict that Adaptive Biotechnologies's share price could reach $8.00 by Nov 13, 2024. The average Adaptive Biotechnologies stock price prediction forecasts a potential upside of 69.85% from the current ADPT share price of $4.71.

(NASDAQ: ADPT) forecast ROE is N/A, which is considered weak.